Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 1 year
- Director since
- 2026
1 year of board service in total across 2 boards, counting each seat separately. Longest: Vera Therapeutics Inc., 6 months.
Vera Therapeutics Inc.
Director
Kailera Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Royalty Pharma plc | Open-market sale | −96,073 | $58.51 | $5,621,692 |
| Sep 22, 2026 | Royalty Pharma plc | Open-market sale | −3,927 | $58.93 | $231,403 |
| Aug 19, 2026 | Royalty Pharma plc | Gift | −16,800 | — | — |
| Aug 18, 2026 | Royalty Pharma plc | Open-market sale | −100,000 | $59.97 | $5,997,250 |
| Aug 5, 2026 | Royalty Pharma plc | Grant or award | +11,002 | — | — |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −97,446 | $56.50 | $5,505,972 |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −2,554 | $57.10 | $145,841 |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −29,400 | $56.44 | $1,659,404 |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −600 | $57.09 | $34,254 |
| Jun 23, 2026 | Royalty Pharma plc | Open-market sale | −32,408 | $54.11 | $1,753,597 |
| Jun 23, 2026 | Royalty Pharma plc | Open-market sale | −117,592 | $54.47 | $6,405,236 |
| May 6, 2026 | Royalty Pharma plc | Grant or award | +24,263 | — | — |
| Feb 11, 2026 | Royalty Pharma plc | Grant or award | +26,626 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.